Blue Lake reports positive data from Phase I RSV vaccine trial

cafead

Administrator
Staff member
  • cafead   Nov 08, 2022 at 11:32: AM
via Blue Lake Biotechnology has reported positive interim findings from a Phase I clinical trial of its intranasal vaccine candidate, BLB201, to prevent severe respiratory syncytial virus (RSV)-linked disease.

article source
 

<